TG Therapeutics, Inc.’s TGTX share price has surged by 10.20%, which has investors questioning if this is right time to sell.
ALX Oncology Holdings Inc.’s ALXO share price has dipped by 15.70%, which has investors questioning if this is right time to buy.
HONG KONG, China I March 7, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company")is excited to announce that the groundbreaking results of the Phase III ...
“In 2024, we delivered strong progress and continued momentum for our clinical development program evaluating evorpacept as a ...
ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 ...
ALX Oncology (ALXO) will highlight progress across its clinical pipeline, including continued advancement of investigational CD47-blocker ...
Event to include updates on ongoing evorpacept clinical development program and introduction of clinical trials in breast and ...
The first patient with small cell lung cancer has been dosed in a trial of peluntamig (PT217) combined with chemotherapy.
Cancer cells, when overexpressed with CD47, send a “don’t eat me” signal to macrophages, successfully shielding them from immune destruction. Similarly, tyrosine kinase inhibitors (TKIs) have ...
Cancer cells, when overexpressed with CD47, send a “don’t eat me” signal to macrophages, successfully shielding them from immune destruction. Similarly, tyrosine kinase inhibitors (TKIs) have ...
Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients with DLL3-expressing cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback